Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophi...

Full description

Bibliographic Details
Main Authors: Paul M L Janssen, Jason D Murray, Kevin E Schill, Neha Rastogi, Eric J Schultz, Tam Tran, Subha V Raman, Jill A Rafael-Fortney
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24551095/pdf/?tool=EBI
id doaj-ab56521f9d8d4acfa90e1e22a0eee762
record_format Article
spelling doaj-ab56521f9d8d4acfa90e1e22a0eee7622021-03-04T11:57:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0192e8836010.1371/journal.pone.0088360Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.Paul M L JanssenJason D MurrayKevin E SchillNeha RastogiEric J SchultzTam TranSubha V RamanJill A Rafael-FortneyDuchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophin and haploinsufficient for utrophin (utrn(+/-);mdx, het mice); both cardiac and skeletal muscle function and histology were improved when these mice were treated early with LS. It was unknown to what extent LS treatment is effective in the most commonly used DMD murine model, the mdx mouse. In addition, current standard-of-care treatment for DMD is limited to corticosteroids. Therefore, potentially useful alternative or additive drugs need to be both compared directly to corticosteroids and tested in presence of corticosteroids. We evaluated the effectiveness of this LS combination in the mdx mouse model both compared with corticosteroid treatment (prednisolone, P) or in combination (LSP). We tested the additional combinatorial treatment containing the angiotensin II receptor blocker losartan (T), which is widely used to halt and treat the developing cardiac dysfunction in DMD patients as an alternative to an ACE inhibitor. Peak myocardial strain rate, assessed by magnetic resonance imaging, showed a negative impact of P, whereas in both diaphragm and extensor digitorum longus (EDL) muscle contractile function was not significantly impaired by P. Histologically, P generally increased cardiac damage, estimated by percentage area infiltrated by IgG as well as by collagen staining. In general, groups that only differed in the presence or absence of P (i.e. mdx vs. P, LS vs. LSP, and TS vs. TSP) demonstrated a significant detrimental impact of P on many assessed parameters, with the most profound impact on cardiac pathology.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24551095/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Paul M L Janssen
Jason D Murray
Kevin E Schill
Neha Rastogi
Eric J Schultz
Tam Tran
Subha V Raman
Jill A Rafael-Fortney
spellingShingle Paul M L Janssen
Jason D Murray
Kevin E Schill
Neha Rastogi
Eric J Schultz
Tam Tran
Subha V Raman
Jill A Rafael-Fortney
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
PLoS ONE
author_facet Paul M L Janssen
Jason D Murray
Kevin E Schill
Neha Rastogi
Eric J Schultz
Tam Tran
Subha V Raman
Jill A Rafael-Fortney
author_sort Paul M L Janssen
title Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_short Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_full Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_fullStr Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_full_unstemmed Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
title_sort prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of duchenne muscular dystrophy.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Duchenne muscular dystrophy (DMD) is an inherited disease that causes striated muscle weakness. Recently, we showed therapeutic effects of the combination of lisinopril (L), an angiotensin converting enzyme (ACE) inhibitor, and spironolactone (S), an aldosterone antagonist, in mice lacking dystrophin and haploinsufficient for utrophin (utrn(+/-);mdx, het mice); both cardiac and skeletal muscle function and histology were improved when these mice were treated early with LS. It was unknown to what extent LS treatment is effective in the most commonly used DMD murine model, the mdx mouse. In addition, current standard-of-care treatment for DMD is limited to corticosteroids. Therefore, potentially useful alternative or additive drugs need to be both compared directly to corticosteroids and tested in presence of corticosteroids. We evaluated the effectiveness of this LS combination in the mdx mouse model both compared with corticosteroid treatment (prednisolone, P) or in combination (LSP). We tested the additional combinatorial treatment containing the angiotensin II receptor blocker losartan (T), which is widely used to halt and treat the developing cardiac dysfunction in DMD patients as an alternative to an ACE inhibitor. Peak myocardial strain rate, assessed by magnetic resonance imaging, showed a negative impact of P, whereas in both diaphragm and extensor digitorum longus (EDL) muscle contractile function was not significantly impaired by P. Histologically, P generally increased cardiac damage, estimated by percentage area infiltrated by IgG as well as by collagen staining. In general, groups that only differed in the presence or absence of P (i.e. mdx vs. P, LS vs. LSP, and TS vs. TSP) demonstrated a significant detrimental impact of P on many assessed parameters, with the most profound impact on cardiac pathology.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24551095/pdf/?tool=EBI
work_keys_str_mv AT paulmljanssen prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
AT jasondmurray prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
AT kevineschill prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
AT neharastogi prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
AT ericjschultz prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
AT tamtran prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
AT subhavraman prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
AT jillarafaelfortney prednisoloneattenuatesimprovementofcardiacandskeletalcontractilefunctionandhistopathologybylisinoprilandspironolactoneinthemdxmousemodelofduchennemusculardystrophy
_version_ 1714803247166783488